<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04230551</url>
  </required_header>
  <id_info>
    <org_study_id>RASTA_V6</org_study_id>
    <nct_id>NCT04230551</nct_id>
  </id_info>
  <brief_title>Reverse Remodeling After PTSMA in Severe But Asymptomatic LVOT Obstruction</brief_title>
  <acronym>RASTA</acronym>
  <official_title>Reverse Remodeling After PTSMA in Severe But ASympTomAtic LVOT Obstruction (RASTA Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Antonius Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Antonius Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with HOCM and severe LVOT obstruction can remain asymptomatic while significant
      cellular and structural changes of the heart (adverse remodeling) may occur preceding heart
      failure and rhythm disorders. Hence, preventing adverse remodeling through LVOT
      desobstruction may have significant impact on cardiac function and geometry in this
      particular population, as it is in symptomatic patients.

      The investigators will assess functional and structural characteristics of the myocardium in
      asymptomatic vs. symptomatic patients with severe LVOT obstruction before and after PTSMA,
      using advanced imaging studies with LGE-CMR and echocardiography.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial consists of three cohorts

        1. Symptomatic HOCM patients with severe LVOT obstruction undergoing PTSMA (reference
           group)

        2. Asymptomatic HOCM patients with severe LVOT obstruction undergoing PTSMA (study group)

        3. Asymptomatic HOCM patients with severe LVOT obstruction with no intervention
           (observation group)
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 21, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Technicians and/or imaging cardiologists involved in image analysis will not be informed about the procedure in order to have an unbiased analysis at baseline. At follow-up, treated patients will have akinetic/infarcted proximal septum that will be noticed during image acquisition. However, the pre-PTSMA status (symptomatic vs. asymptomatic) will be blinded for the analysis.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Fibrosis</measure>
    <time_frame>2 years</time_frame>
    <description>Extracellular Volume Fraction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Global longitudinal strain (TTE)</measure>
    <time_frame>2 years</time_frame>
    <description>Diastolic Function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Deformation (CMR)</measure>
    <time_frame>2 years</time_frame>
    <description>Shortening Index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Haemodynamics</measure>
    <time_frame>2 years</time_frame>
    <description>Left and Right-Sided Pressure Gradients (TTE)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>4D velocity mapping</measure>
    <time_frame>2 years</time_frame>
    <description>Blood Flow</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LV Geometry</measure>
    <time_frame>2 years</time_frame>
    <description>Volume</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) classification</measure>
    <time_frame>2 years</time_frame>
    <description>Exercise tolerance</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>HOCM, Hypertrophic Obstructive Cardiomyopathy</condition>
  <condition>LVOTO - Left Ventricular Outflow Tract Obstruction</condition>
  <condition>Remodeling, Ventricular</condition>
  <arm_group>
    <arm_group_label>Reference Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Five symptomatic HOCM patients with severe LVOT obstruction will undergo PTSMA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Five asymptomatic HOCM patients with severe LVOT obstruction will undergo PTSMA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Five asymptomatic HOCM patients with severe LVOT obstruction will not undergo PTSMA</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PTSMA</intervention_name>
    <description>Alcohol Septal Ablation</description>
    <arm_group_label>Reference Group</arm_group_label>
    <arm_group_label>Study Group</arm_group_label>
    <other_name>Alcohol Septal Ablation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 40 yrs

          -  HOCM diagnosed by experienced cardiologists (European Society of Cardiology
             (ESC)-certified imaging cardiologists and/or finalized fellowship imaging)

          -  LVOT obstruction &gt;30 mmHg pressure gradient in rest, or &gt;50 mmHg during exercise by
             TTE and/or invasive measurement, performed experienced (imaging) cardiologists

          -  Symptomatic (NYHA class &gt;2 or CCS class &gt;2)

          -  Asymptomatic: free of any dyspnea/chest pain or discomfort associated with LVOT
             obstruction

        Exclusion Criteria:

          -  LV wall thickness &lt;15 mm

          -  Other conditions responsible for hypertrophy (e.g. hypertension, aortic valve disease)

          -  Moderate to severe mitral valve regurgitation

          -  Systolic anterior motion of the mitral valve

          -  Coronary artery disease requiring intervention

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jurrien M ten Berg, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Antonius Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fatih Arslan, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Antonius Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jurrien M ten Berg, MD PhD</last_name>
    <phone>+31 88 320 1121</phone>
    <email>j.ten.berg@antoniusziekenhuis.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Jurrien M ten Berg, MD PhD</last_name>
      <phone>+31 88 320 1121</phone>
      <email>j.ten.berg@antoniusziekenhuis.nl</email>
    </contact>
    <contact_backup>
      <last_name>Fatih Arslan, MD PhD</last_name>
      <email>f.arslan@antoniusziekenhuis.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Fatih Arslan, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 31, 2019</study_first_submitted>
  <study_first_submitted_qc>January 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>January 13, 2020</last_update_submitted>
  <last_update_submitted_qc>January 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Antonius Hospital</investigator_affiliation>
    <investigator_full_name>J.M. ten Berg</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>HOCM</keyword>
  <keyword>Hypertrophic Obstructive Cardiomyopathy</keyword>
  <keyword>Left Ventricular Outflow Tract Obstruction</keyword>
  <keyword>Adverse Remodeling</keyword>
  <keyword>Reverse Remodeling</keyword>
  <keyword>Alcohol Septal Ablation</keyword>
  <keyword>Percutaneous Transluminal Septal Myocardial Ablation</keyword>
  <keyword>PTSMA</keyword>
  <keyword>Extracellular Volume Fraction</keyword>
  <keyword>Global Longitudinal Strain</keyword>
  <keyword>Deformation Imaging</keyword>
  <keyword>4D Velocity Mapping</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Ventricular Remodeling</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

